Skip to content

Advanced MRI techniques and biomarkers to substitute gadolinium enhanced MRI for the detection of disease activity in multiple sclerosis.

Advanced MRI techniques and biomarkers to substitute gadolinium enhanced MRI for the detection of disease activity in multiple sclerosis. - ACTIVITY

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON53657
Enrollment
75
Registered
2023-01-25
Start date
2023-11-17
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis Multiple Sclerosis

Interventions

MRI

Sponsors

Amsterdam UMC
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: To be eligible for this study, the participant must meet the following criteria: Diagnosed as CIS, RRMS, PPMS based on McDonald criteria (2017) Adult (18-70 years old) Signed informed consent Separate inclusion criteria will be applied for the active and inactive subgroup: For the active subgroup: one or more Gd-enhancing lesion on brain MRI or signs of clinical disease activity For the inactive subgroup: no Gd enhancing lesion on brain MRI and no clinical signs of disease activity.

Exclusion criteria

Exclusion criteria: A potential participant will be excluded from the study based on the following criteria: contra-indications for MRI Pregnancy History of (psychiatric) disorder which causes the patient to be incompetent to make a well-informed decision Other concurrent neurological disease

Design outcomes

Primary

MeasureTime frame
1) Establishing differences in image characteristics of Gd enhancing and non-enhancing lesions on the advanced MRI sequences. 2) Establishing differences in image characteristics on the advanced MRI sequences between new lesions and previously present lesions. 3) Establishing differences between blood biomarker levels between participants with and without Gd enhancing lesions.

Secondary

MeasureTime frame
Not applicable.

Countries

Netherlands

Contacts

Public ContactE. Donders

Amsterdam UMC

e.donders@amsterdamumc.nl0204442060

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Jun 11, 2026